Barclays PLC Travere Therapeutics, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 177,757 shares of TVTX stock, worth $1.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
177,757
Previous 386,809
54.05%
Holding current value
$1.4 Million
Previous $3.48 Million
60.63%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.5MCall Options Held
66.9KPut Options Held
265K-
Black Rock Inc. New York, NY7.8MShares$61.5 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$59.2 Million0.79% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$58.1 Million1.88% of portfolio
-
State Street Corp Boston, MA6.61MShares$52.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.27MShares$49.4 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $506M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...